Get started
Author

Daniel Magoon

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 · Johannes Zuber, Junwei Shi, et al. · Nature · 1,870
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
2015 · Mignon L. Loh, Sarah K. Tasian, et al. · Pediatric Blood & Cancer · 132
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
2013 · Edward Allan R. Sison, Emily McIntyre, et al. · Molecular Cancer Research · 107
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)
2017 · Todd M. Cooper, Edward Allan Racela Sison, et al. · Pediatric Blood & Cancer · 79
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2016 · Todd M. Cooper, Jeannette Cassar, et al. · Clinical Cancer Research · 75
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
2014 · Edward Allan R. Sison, Daniel Magoon, et al. · Oncotarget · 65
PDF
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
2015 · Edward Allan R. Sison, Daniel Magoon, et al. · Oncotarget · 38
PDF
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease
2013 · Rachel Rau, Daniel Magoon, et al. · Experimental Hematology · 35
PDF
Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
2018 · Colleen E. Annesley, Cara Rabik, et al. · Oncotarget · 8
PDF
A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study
2013 · Todd Michael Cooper, Jemily Malvar, et al. · Blood · 7
A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2012 · Todd Cooper, Richard Sposto, et al. · Blood · 7
Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS
2013 · Todd Michael Cooper, Sharyn D. Baker, et al. · Blood · 5
Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.
2012 · Di Sun, Allison Kaeding, et al. · Journal of Clinical Oncology · 3
A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations
2015 · Colleen E. Annesley, Amy S. Duffield, et al. · Blood · 1
POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)
2014 · Edward Allan R. Sison, Daniel Magoon, et al. · Blood · 1
Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL)
2013 · Edward Allan R. Sison, Daniel Magoon, et al. · Blood · 1
The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)
2012 · Edward Allan R. Sison, Daniel Magoon, et al. · Blood · 1
Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia
2011 · Edward Allan R. Sison, Daniel Magoon, et al. · Blood · 1
Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia
2010 · Edward Allan R. Sison, Emily McIntyre, et al. · Blood · 1
Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model
2010 · Rachel E. Rau, Daniel Magoon, et al. · Blood · 1
A-109 Validation of a Multiplexed External Control Panel to Monitor the Performance of the Roche cobas® eplex respiratory pathogen panel 3
2026 · Nithya Sivaji, Jack Aldana Proulx, et al. · Clinical Chemistry
Supplemental Figures and Tables from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2023 · Todd M. Cooper, Jeannette Cassar, et al.
Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2023 · Todd M. Cooper, Jeannette Cassar, et al.
Data from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2023 · Todd M. Cooper, Jeannette Cassar, et al.
Data from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
2023 · Todd M. Cooper, Jeannette Cassar, et al.
Works count: 35
Citation count: 2,438
H-index: 8
I10-index: 8
Year
Topic
Type